Scribe Therapeutics Inc. (NASDAQ:SCTX – Get Free Report) Director Behzad Aghazadeh bought 7,905 shares of the business’s stock in a transaction on Tuesday, July 28th. The shares were bought at an average cost of $18.25 per share, for a total transaction of $144,266.25. Following the completion of the acquisition, the director directly owned 3,088,888 shares in the company, valued at approximately $56,372,206. This trade represents a 0.26% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Behzad Aghazadeh also recently made the following trade(s):
- On Friday, July 24th, Behzad Aghazadeh purchased 2,383,333 shares of Scribe Therapeutics stock. The stock was bought at an average price of $15.15 per share, for a total transaction of $36,107,494.95.
Scribe Therapeutics Stock Performance
Shares of SCTX stock opened at $18.06 on Wednesday. Scribe Therapeutics Inc. has a 1-year low of $17.31 and a 1-year high of $25.49.
Featured Stories
- Five stocks we like better than Scribe Therapeutics
- These 3 Stocks Have Soared in 2026—Can They Keep Climbing?
- Hasbro’s Earnings Beat Shows Why This Is No Longer Just a Toy Story
- Rambus: Another AI Phoenix Ready to Rise From the Ashes of Correction
- Chips & Clips: Memory Tariffs Rewire Tech Supply Chains
Receive News & Ratings for Scribe Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scribe Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
